Figure 3.

Defined spatial- and core-specific stages of non-senescent, p16-senescent, and regressed HHs. (A) Percentual distribution of p16⁺ cells in non-senescent, p16-senescent, and regressed hemangiomas after digital senescence classification. Cutoff for p16-positivity was set to 10%. (B) Percentual distribution of non-senescent, p16-senescent, and regressed hemangiomas after HH classification. (C) Correlation analysis between p16⁺ and p53⁺ cell numbers in HH cores (Spearman correlation analysis). (D) Low and high magnification of H&E, p16, p16⁺ cell detection, p53, p53⁺ cell detection, and Ki67 in non-senescent, p16-senescent, and regressed hemangiomas. Arrow indicates a Ki67⁺ EC in a non-senescent HH. Scale bar: 250 µm (low) and 20 µm (high). Abbreviations: HH, hepatic hemangioma; H&E, haematoxylin eosin; EC, endothelial cell.